Skip to main content

Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.

Publication ,  Journal Article
McGlasson, DL; Kaczor, DA; Krasuski, RA; Campbell, CL; Kostur, MR; Adinaro, JT
Published in: Blood Coagul Fibrinolysis
April 2005

The purpose of this study was to determine whether the anti-activated factor X (anti-FXa) assay is less affected by pre-analytical variables in monitoring patients on unfractionated heparin (UFH) and low molecular weight heparin (LMWH) than the activated partial thromboplastin time (aPTT). Forty-six subjects receiving either enoxaparin (LMWH) or UFH were randomly selected. Each study subject had six vacutainer tubes (3.8% sodium citrate, 3.2% sodium citrate) drawn by an atraumatic venipuncture. One tube from each set had a blood to anticoagulant ratio of 9: 1. The other tube had an intentional "short-draw" of approximately 6: 1 blood to anticoagulant ratio. All specimens had an aPTT and a chromogenic anti-FXa assay performed on each specimen regardless of heparin type. The aPTT assay mean with the 3.8% sodium citrate tube short-draw tube was statistically different from the other aPTT assays (P = 0.06). However, all six of the mean anti-FXa assays for the UFH and LMWH heparin subjects were not statistically or clinically different (analysis of variance, P = 0.9878 for UFH and P = 0.9060 for LMWH). The intentional short-draw tube did not affect the anti-FXa assay regardless of the anticoagulant. The anti-FXa assay appears to be a better method for monitoring heparin subjects than the aPTT due to the lack of effect of pre-analytical variables.

Duke Scholars

Published In

Blood Coagul Fibrinolysis

DOI

ISSN

0957-5235

Publication Date

April 2005

Volume

16

Issue

3

Start / End Page

173 / 176

Location

England

Related Subject Headings

  • Partial Thromboplastin Time
  • Middle Aged
  • Male
  • Humans
  • Heparin, Low-Molecular-Weight
  • Heparin
  • Female
  • Factor X
  • Enoxaparin
  • Drug Monitoring
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McGlasson, D. L., Kaczor, D. A., Krasuski, R. A., Campbell, C. L., Kostur, M. R., & Adinaro, J. T. (2005). Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagul Fibrinolysis, 16(3), 173–176. https://doi.org/10.1097/01.mbc.0000164424.90545.6e
McGlasson, David L., Daniel A. Kaczor, Richard A. Krasuski, Charles L. Campbell, Maria R. Kostur, and Joseph T. Adinaro. “Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.Blood Coagul Fibrinolysis 16, no. 3 (April 2005): 173–76. https://doi.org/10.1097/01.mbc.0000164424.90545.6e.
McGlasson DL, Kaczor DA, Krasuski RA, Campbell CL, Kostur MR, Adinaro JT. Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagul Fibrinolysis. 2005 Apr;16(3):173–6.
McGlasson, David L., et al. “Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.Blood Coagul Fibrinolysis, vol. 16, no. 3, Apr. 2005, pp. 173–76. Pubmed, doi:10.1097/01.mbc.0000164424.90545.6e.
McGlasson DL, Kaczor DA, Krasuski RA, Campbell CL, Kostur MR, Adinaro JT. Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. Blood Coagul Fibrinolysis. 2005 Apr;16(3):173–176.

Published In

Blood Coagul Fibrinolysis

DOI

ISSN

0957-5235

Publication Date

April 2005

Volume

16

Issue

3

Start / End Page

173 / 176

Location

England

Related Subject Headings

  • Partial Thromboplastin Time
  • Middle Aged
  • Male
  • Humans
  • Heparin, Low-Molecular-Weight
  • Heparin
  • Female
  • Factor X
  • Enoxaparin
  • Drug Monitoring